vs
Side-by-side financial comparison of TSS, Inc. (TSSI) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $60.9M, roughly 1.7× TSS, Inc.). TSS, Inc. runs the higher net margin — 20.0% vs -29.4%, a 49.4% gap on every dollar of revenue. On growth, TSS, Inc. posted the faster year-over-year revenue change (21.8% vs 16.9%). TSS, Inc. produced more free cash flow last quarter ($15.8M vs $-34.8M).
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
TSSI vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $60.9M | $103.7M |
| Net Profit | $12.2M | $-30.5M |
| Gross Margin | 17.6% | 52.0% |
| Operating Margin | 1.5% | -31.7% |
| Net Margin | 20.0% | -29.4% |
| Revenue YoY | 21.8% | 16.9% |
| Net Profit YoY | 535.7% | 3.4% |
| EPS (diluted) | $0.44 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $60.9M | $103.7M | ||
| Q3 25 | $41.9M | — | ||
| Q2 25 | $44.0M | — | ||
| Q1 25 | $99.0M | — | ||
| Q4 24 | $50.0M | — | ||
| Q3 24 | $70.1M | — | ||
| Q2 24 | $12.2M | — | ||
| Q1 24 | $15.9M | — |
| Q4 25 | $12.2M | $-30.5M | ||
| Q3 25 | $-1.5M | — | ||
| Q2 25 | $1.5M | — | ||
| Q1 25 | $3.0M | — | ||
| Q4 24 | $1.9M | — | ||
| Q3 24 | $2.6M | — | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $15.0K | — |
| Q4 25 | 17.6% | 52.0% | ||
| Q3 25 | 11.1% | — | ||
| Q2 25 | 17.8% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 14.4% | — | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 17.1% | — |
| Q4 25 | 1.5% | -31.7% | ||
| Q3 25 | -2.2% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 5.4% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | 20.0% | -29.4% | ||
| Q3 25 | -3.6% | — | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 11.5% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | $0.44 | $-0.50 | ||
| Q3 25 | $-0.06 | — | ||
| Q2 25 | $0.06 | — | ||
| Q1 25 | $0.12 | — | ||
| Q4 24 | $0.08 | — | ||
| Q3 24 | $0.10 | — | ||
| Q2 24 | $0.06 | — | ||
| Q1 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $85.5M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $76.6M | $456.1M |
| Total Assets | $184.9M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $85.5M | $197.9M | ||
| Q3 25 | $70.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $23.2M | — | ||
| Q3 24 | $46.4M | — | ||
| Q2 24 | $8.3M | — | ||
| Q1 24 | $14.4M | — |
| Q4 25 | $76.6M | $456.1M | ||
| Q3 25 | $63.4M | — | ||
| Q2 25 | $9.5M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $7.1M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $3.7M | — |
| Q4 25 | $184.9M | $638.1M | ||
| Q3 25 | $165.4M | — | ||
| Q2 25 | $139.5M | — | ||
| Q1 25 | $113.5M | — | ||
| Q4 24 | $96.6M | — | ||
| Q3 24 | $67.3M | — | ||
| Q2 24 | $28.9M | — | ||
| Q1 24 | $26.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $-24.8M |
| Free Cash FlowOCF − Capex | $15.8M | $-34.8M |
| FCF MarginFCF / Revenue | 25.9% | -33.5% |
| Capex IntensityCapex / Revenue | 0.9% | 9.6% |
| Cash ConversionOCF / Net Profit | 1.34× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $-24.8M | ||
| Q3 25 | $-18.4M | — | ||
| Q2 25 | $16.3M | — | ||
| Q1 25 | $20.6M | — | ||
| Q4 24 | $-21.6M | — | ||
| Q3 24 | $38.6M | — | ||
| Q2 24 | $-4.3M | — | ||
| Q1 24 | $2.6M | — |
| Q4 25 | $15.8M | $-34.8M | ||
| Q3 25 | $-24.9M | — | ||
| Q2 25 | $5.4M | — | ||
| Q1 25 | $5.8M | — | ||
| Q4 24 | $-28.4M | — | ||
| Q3 24 | $38.6M | — | ||
| Q2 24 | $-6.0M | — | ||
| Q1 24 | $2.6M | — |
| Q4 25 | 25.9% | -33.5% | ||
| Q3 25 | -59.3% | — | ||
| Q2 25 | 12.3% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | -56.7% | — | ||
| Q3 24 | 55.1% | — | ||
| Q2 24 | -49.4% | — | ||
| Q1 24 | 16.4% | — |
| Q4 25 | 0.9% | 9.6% | ||
| Q3 25 | 15.3% | — | ||
| Q2 25 | 24.8% | — | ||
| Q1 25 | 15.0% | — | ||
| Q4 24 | 13.4% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | 1.34× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 11.02× | — | ||
| Q1 25 | 6.93× | — | ||
| Q4 24 | -11.32× | — | ||
| Q3 24 | 14.60× | — | ||
| Q2 24 | -3.09× | — | ||
| Q1 24 | 176.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TSSI
| Procurement Revenues Segment | $43.2M | 71% |
| System Integration Services Segment | $14.2M | 23% |
| Facilities Segment | $3.5M | 6% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
